Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

AbbVie Inc. (NYSE:ABBV) shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share ...

Ubrelvy (ubrogepant) is a prescription drug that treats migraine episodes. This drug can interact with certain other medications and some supplements. For example, Ubrelvy can interact with ...

Represents net earnings attributable to AbbVie Inc. Intangible asset impairment reflects a partial after-tax impairment charge of $3.5 billion related to the emraclidine intangible asset acquired as ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

Neuroscience sales are likely to have been driven by the depression drug Vraylar and new migraine drugs — Ubrelvy and Qulipta. In November, AbbVie gained approval for Vyalev, a transformative ...

In the ad for oral CGRP inhibitor Ubrelvy (ubrogepant), Williams is depicted as suffering from a migraine while in a talk show dressing room, which resolves by the time she walks onto the set and ...

AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...

Live Updates Make sure to refresh this page periodically for updates. Deep Dive into ABBV's Earnings Call 01/01/1970 12:00 am ...

Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...